Core Insights - F5, Inc. reported strong second-quarter fiscal 2025 results, with non-GAAP earnings of $3.42 per share, exceeding estimates by 10.3% and management's guidance [1] - Revenues for the quarter reached $731 million, surpassing the consensus mark by 2% and increasing 7.3% year-over-year [2] Financial Performance - Product revenues, accounting for 46.1% of total revenues, grew 12% year-over-year to $337.2 million, driven by a 27% increase in Systems revenues to $179 million [3] - Software revenues remained flat at $158 million compared to the previous year [4] - Global Services revenues, making up 53.9% of total revenues, increased 3% year-over-year to $393.9 million [4] - Non-GAAP gross margin expanded by 100 basis points to 83.1% from 82.1% a year ago [5] Balance Sheet & Cash Flow - F5 ended the quarter with cash and short-term investments of $1.26 billion, up from $1.16 billion in the previous quarter [6] - The company generated operating cash flow of $257 million, an increase from $203 million in the prior quarter [6] - F5 repurchased shares worth $252.1 million during the quarter [6] Guidance - F5 raised its fiscal 2025 revenue growth forecast to 6.5-7.5%, up from the previous 6-7% estimate [7] - Non-GAAP earnings per share growth is now projected at 8-10%, compared to the earlier estimate of 6.5-8.5% [8] - For the third quarter of fiscal 2025, F5 expects revenues between $740 million and $760 million [8] - The projected non-GAAP EPS for the third quarter is in the range of $3.41-$3.53 [9]

Core Insights - American Tower (AMT) reported a revenue of $2.56 billion for the quarter ended March 2025, reflecting a year-over-year decline of 9.6% but exceeding the Zacks Consensus Estimate by 1.98% [1] - The earnings per share (EPS) for the quarter was $2.75, an increase from $1.96 in the same quarter last year, surpassing the consensus EPS estimate by 5.77% [1] Financial Performance - The stock has returned -2.9% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3] - The total ending balance for U.S. & Canada was 41,868, slightly above the average estimate of 41,759, while the total ending balance was 148,637, below the average estimate of 173,697 [4] - Organic Tenant Billings Growth for Total International was 6.7%, exceeding the average estimate of 5.7%, while U.S. & Canada growth was 3.6%, slightly below the 3.8% estimate [4] Geographic Revenue Breakdown - Geographic revenues for U.S. & Canada were reported at $1.30 billion, matching the average estimate but showing a -1% year-over-year change [4] - Total International geographic revenues were $946 million, surpassing the average estimate of $896.32 million, but reflecting a significant -25.5% year-over-year decline [4] - Latin America revenues were $399 million, above the average estimate of $381.27 million, with a -10.5% year-over-year change, while Europe revenues were $213 million, slightly above the average estimate of $210 million, showing a +3.9% year-over-year increase [4] Operating Revenues - Total operating revenues from Data Centers were $244 million, below the average estimate of $250.28 million but representing an +8.4% year-over-year increase [4] - Total operating revenues from Services reached $75 million, significantly exceeding the average estimate of $60.28 million, marking a +150% change compared to the year-ago quarter [4] - Total Property operating revenues were reported at $2.49 billion, above the average estimate of $2.45 billion, but reflecting an -11.3% year-over-year decline [4]

Core Insights - Astrazeneca reported $13.59 billion in revenue for Q1 2025, a year-over-year increase of 7.2% [1] - The EPS for the same period was $1.24, compared to $1.03 a year ago, representing a surprise of +12.73% over the consensus estimate [1][3] - The revenue fell short of the Zacks Consensus Estimate by -0.66% [1] Financial Performance - Astrazeneca's stock has returned -4.9% over the past month, underperforming the Zacks S&P 500 composite's -0.8% change [3] - The company currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3] Key Product Metrics - Oncology product Tagrisso generated $678 million in the U.S., slightly below the average estimate of $684.78 million [4] - BioPharmaceuticals product Farxiga in Established RoW reported $120 million, exceeding the estimate of $101.67 million, with a year-over-year change of +11.1% [4] - Oncology product Enhertu in Established RoW achieved $19 million, compared to the estimate of $21.59 million, reflecting a year-over-year increase of +46.2% [4] - Enhertu in Europe reported $43 million, surpassing the estimate of $36.98 million, with a year-over-year change of +65.4% [4] - BioPharmaceuticals product Symbicort generated $723 million, below the estimate of $772.02 million [4] - Pulmicort reported $158 million, compared to the estimate of $197.96 million [4] - Crestor achieved $316 million, exceeding the estimate of $294.03 million, with a year-over-year change of +6.4% [4] - Seloken/Toprol-XL reported $161 million, slightly above the estimate of $154.45 million, with a year-over-year change of -2.4% [4] - Tagrisso worldwide generated $1.68 billion, slightly above the estimate of $1.67 billion, reflecting a year-over-year change of +5.3% [4] - Synagis reported $112 million, below the estimate of $132.88 million, with a year-over-year change of -34.5% [4] - Fasenra achieved $418 million, exceeding the estimate of $379.51 million [4] - Brilinta reported $305 million, above the estimate of $263.03 million, with a year-over-year change of -5.6% [4]

一季报的披露马上就要结束了，很多人都说业绩好的公司接下来将会成为整个5月份的市场主线，特别 是一些估值水平比较低，同时现金流又比较好的公司。4月29日，和讯投顾王偲安分析，说到这里，一 定绕不开白酒这个行业，毫无疑问白酒的基本面是不错的，但是为什么每次的反弹它都没有持续性？首 先我们随便打开一家白酒公司的财报，仔细去看它的资产负债表，你就会发现一个问题，就是货币资金 占总资产比例特别大，尤其是行业的龙头公司，总资产里面居然有超过60%都是货币资金，从一个方面 来讲说明公司的现金很充足，不会出现财务风险，但是从另外一个角度来看，是不是同时也说明公司的 资金使用效率很低，你想想钱都趴在账上，不去投入生产和市场建设，那么它未来的业绩增长拿什么来 保证？所以这也就解释了整个白酒行业现在的估值水平为什么这么低了。 第二步打开利润表，我们只看两个指标，就是毛利率和净利率，大家会发现一个点，白酒公司的毛利率 和净利率这些年它都是逐步走高的，按理来说这个赛道应该还处在成长期，因为毛利率高代表行业好， 净利率高，代表管理水平高，但是大家有没有想过，白酒行业这些年基本上没有怎么去扩充产能，但是 它的产量却在稳定增长，这是不是说明 ...

三、分红送配方案情况 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 9946.21万股，累计占流通股比： 52.67%，较上期变化： 162.17万股。 | 名称 | 持有数量(万股) | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- | --- | | 陈洪民 | 3893.70 | 20.62 | 不变 | | 上海晶优新能源有限公司 | 2169.14 | 11.49 | 不变 | | 张宇 | 1600.80 | 8.48 | 不变 | | 陈伟 | 672.34 | 3.56 | 不变 | | 陈小科 | 560.12 | 2.97 | 不变 | | 江苏科华投资管理有限公司 | 388.92 | 2.06 | 不变 | | 郑文涌 | 210.11 | 1.11 | 新进 | | 薛勇 | 189.43 | 1.00 | 不变 | | 科华控股（603161）股份有限公司回购专用证券账 | | | | | 户 | 134.62 | 0.71 | 不变 | | 高盛公司有限责任公司 | 127.03 | 0.67 | 新 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 李刚 | 1074.50 | 19.19 | 不变 | | 中新苏州工业园区创业投资有限公司 | 249.93 | 4.46 | -30.00 | | 上海华芯创业投资企业 | 216.49 | 3.87 | -47.71 | | 苏州昶众企业管理咨询中心(有限合伙) | 185.00 | 3.30 | 不变 | | 梅嘉欣 | 167.04 | 2.98 | 不变 | | 胡维 | 158.50 | 2.83 | 不变 | | 信澳先进智造股票型 | 144.85 | 2.59 | 3.30 | | 苏州工业园区创业投资引导基金管理中心 | 124.23 | 2.22 | 不变 | | 信澳领先增长混合A | 116.03 | 2.07 | 12.10 | | 苏州昶恒企业管理咨询企业(有限合伙) | 93.86 | 1.68 | 不变 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 | 报告期指标 | 2025年一 ...

Financial Performance - The company reported a basic earnings per share (EPS) of 0.0170 yuan for Q1 2025, representing a 13.33% increase compared to 0.0150 yuan in Q1 2024, but a decrease from 0.0280 yuan in Q1 2023 [1] - The total revenue for Q1 2025 was 120.49 billion yuan, showing a 19.97% increase from 100.43 billion yuan in Q1 2024 and an increase from 104 billion yuan in Q1 2023 [1] - The net profit for Q1 2025 was 0.23 billion yuan, a 9.52% increase from 0.21 billion yuan in Q1 2024, but a decrease from 0.39 billion yuan in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 0.66%, up 22.22% from 0.54% in Q1 2024, but down from 1.04% in Q1 2023 [1] - The net asset per share decreased by 8.63% to 2.54 yuan in Q1 2025 from 2.78 yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 66,655.07 million shares, accounting for 48.62% of the circulating shares, with a decrease of 500.35 million shares compared to the previous period [1] - The largest shareholder, Baosheng Group Co., Ltd., holds 43,740.64 million shares, representing 31.90% of the total share capital, with no change [2] - The second-largest shareholder, Anyi Junjing Shengda Equity Investment Partnership (Limited Partnership), holds 6,857.68 million shares, a decrease of 649.00 million shares [2] - New entrants among the top shareholders include Bi Sheng, Hong Xiaoping, and Lan Yun, each holding 339.02 million, 315.00 million, and 289.97 million shares respectively [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [2]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0040 | 0.0050 | -20 | 0.0050 | | 每股净资产（元） | 2.34 | 2.31 | 1.3 | 2.3 | | 每股公积金(元) | 0.27 | 0.27 | 0 | 0.27 | | 每股未分配利润(元) | 0.82 | 0.80 | 2.5 | 0.79 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.07 | 2.25 | -8 | 2.43 | | 净利润(亿元) | 0.07 | 0.07 | 0 | 0.08 | | 净资产收益率(%) | 0.19 | 0.22 | -13.64 | 0.22 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 61020.99万股，累计占流通股比： 41.77%，较上期变化： -897.51万股。 ...

| 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 国投种业科技有限公司 | 12280.30 | 20.00 | 不变 | | 合肥市建设投资控股(集团)有限公司 | 5673.99 | 9.24 | 不变 | | 嘉实农业产业股票A | 1220.57 | 1.99 | -85.53 | | 宋钢 | 444.25 | 0.72 | 53.16 | | 朱黎辉 | 410.02 | 0.67 | -2.00 | | 海南波莲科技有限公司 | 405.00 | 0.66 | 2.00 | | 基本养老保险基金九零三组合 | 358.16 | 0.58 | 新进 | | 戴飞 | 321.78 | 0.52 | 10.00 | | 丁建军 | 318.94 | 0.52 | 45.83 | | 王淑芬 | 294.45 | 0.48 | 13.85 | | 较上个报告期退出前十大股东有 | | | | | 万家内需增长一年持有期混合 | 373.40 | 0.61 | 退出 | 一、主要会计数据和财务指标 三、分红送配方案情 ...

山鹰国际（600567）公告，2025年第一季度营收为67.66亿元，同比增长1.45%；净利润为3281.45万 元，同比下降16.00%。 ...